Last: | $20.96 |
---|---|
Change Percent: | 4.59% |
Open: | $20.56 |
Close: | $20.96 |
High: | $21.05 |
Low: | $20.49 |
Volume: | 119,496 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$20.96 | $20.56 | $20.96 | $21.05 | $20.49 | 119,496 | 05-16-2024 |
$21.55 | $21.5 | $21.55 | $21.56 | $21.32 | 147,588 | 05-15-2024 |
$21.4 | $21.79 | $21.4 | $21.79 | $21.3 | 83,767 | 05-14-2024 |
$21.78 | $21.82 | $21.78 | $21.87 | $21.42 | 121,227 | 05-13-2024 |
$21.75 | $21.6 | $21.75 | $21.92 | $21.55 | 316,285 | 05-10-2024 |
$20.82 | $20.71 | $20.82 | $21.2 | $20.49 | 272,835 | 05-09-2024 |
$19.47 | $19.2 | $19.47 | $19.51 | $19.19 | 76,857 | 05-08-2024 |
$19.45 | $19.58 | $19.45 | $19.62 | $19.06 | 104,979 | 05-07-2024 |
$19.82 | $19.87 | $19.82 | $19.98 | $19.59 | 202,576 | 05-06-2024 |
$19.15 | $19.54 | $19.15 | $19.54 | $19 | 155,159 | 05-03-2024 |
$19.56 | $19.35 | $19.56 | $19.58 | $19.0107 | 120,034 | 05-02-2024 |
$18.76 | $18.31 | $18.76 | $18.96 | $18.31 | 30,266 | 05-01-2024 |
$18.51 | $18.6 | $18.51 | $18.89 | $18.3959 | 54,130 | 04-30-2024 |
$18.91 | $19.3 | $18.91 | $19.41 | $18.6 | 267,609 | 04-29-2024 |
$18.16 | $18.99 | $18.16 | $18.99 | $17.46 | 185,467 | 04-26-2024 |
$18.99 | $18.66 | $18.99 | $19.23 | $18.54 | 119,074 | 04-25-2024 |
$18.41 | $18.66 | $18.41 | $18.73 | $18.1 | 57,768 | 04-24-2024 |
$18.25 | $17.64 | $18.25 | $18.46 | $17.64 | 121,611 | 04-23-2024 |
$16.94 | $16.78 | $16.94 | $17.02 | $16.69 | 148,847 | 04-22-2024 |
$16.5 | $16.31 | $16.5 | $16.53 | $16.21 | 61,049 | 04-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
4.59%Change Percent:
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) tod...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data rela...
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui...